Application of Colorectal Cancer Early Screening Based on Multitarget Fecal FIT-DNA Joint Detection Technology
10.3971/j.issn.1000-8578.2024.23.1364
- VernacularTitle:基于多靶点粪便FIT-DNA联合检测技术的结直肠癌早筛应用研究
- Author:
Jie WANG
1
;
Mingxing HOU
1
;
Haidong CHENG
1
;
Yongqiang LIU
1
;
Jie MIAO
1
;
Shuwen LI
1
;
Lu CHEN
1
Author Information
1. Department of Gastrointestinal Surgery, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China.
- Publication Type:CLINICALRESEARCH
- Keywords:
Combined detection of multitarget fecal FIT-DNA;
Serum tumor markers;
Colorectal cancer;
Early screening;
Enteroscopy
- From:
Cancer Research on Prevention and Treatment
2024;51(7):578-582
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and further analyze the application prospects of the combined multitarget fecal FIT-DNA assay in the early screening of colorectal cancer. Methods Subjects were selected from a population attending the Inner Mongolia Medical University Hospital. Each subject underwent a combined multi-target fecal FIT-DNA test (experimental group), a serum tumor marker test and enteroscopy (control group). The pathological results were used as the gold standard to evaluate the efficacy of novel fecal molecular testing techniques for colorectal cancer screening with timely intervention given to screen positive individuals. Results The data of 115 individuals were analyzed. Serum tumor markers test had a sensitivity of 63.2% (43/68) and a specificity of 74.5% (35/47). The enteroscopy had a sensitivity of 97.1% (66/68) and a specificity of 80.7% (38/47); the combined multitarget fecal FIT-DNA test had a sensitivity of 89.7% (61/68) and a specificity of 87.2% (41/47). Conclusion The sensitivity and specificity of multitarget fecal FIT-DNA combined detection are better than those of serum tumor marker detection. Although its sensitivity is lower than enteroscopy, its operation is simpler and can be tested at home.
